Pomalidomide With Low-Dose Dexamethasone New Treatment Option for Multiple Myeloma

Pomalidomide, an immunomodulatory drug, combined with low-dose dexamethasone improved progression-free survival in patients with refractory or relapsed and refractory multiple myeloma compared with standard of care high-dose dexamethasone, according to the results of a multicenter, open-label, phase III trial.

Although prior research has shown that pomalidomide has efficacy in patients refractory to lenalidomide and bortezomib, it had not yet been compared with existing standard of care treatments in relapsed or refractory myeloma